Abstract: Various pharmaceutical applications of low-molecular-weight hyaluronic acid (LMW-HA) fragments include: treating tumors, conjunctival diseases, xerophthalmia, vitreous opacity, myofascitis, arthritis, cardiovascular diseases, cerebral infarction, dysmenorrhea, endometriosis, periodontal diseases, herpes zoster, burns, pains, pruritus, acute pancreatitis, and postoperative abdominal mucosal adhesions, helping with body recovery after chemotherapy and facial cosmesis, reducing subcutaneous fat etc. Moreover, an injection containing the LMW-HA fragments and a preparation method thereof are disclosed. The injection is injected into the subcutaneous fat layer of the abdomen for facial cosmesis and anti-aging.

Abstract: Various pharmaceutical applications of low-molecular-weight hyaluronic acid (LMW-HA) fragments include: treating tu-mors, conjunctival diseases, xerophthalmia, vitreous opacity, myofascitis, arthritis, cardiovascular diseases, cerebral infaretion, dysmenorrhea, endometriosis, periodontal diseases, herpes zoster, burns, pains, pruritus, acute pancreatitis, and postoperative abdominal mucosal adhesions, helping with body recovery after chemotherapy and facial cosmesis, reducing subcutaneous fat etc. Moreover, an injection containing the LMW-HA fragments and a preparation method thereof are disclosed. The injection is injected into the subcutaneous fat layer of the abdomen for facial cosmesis and anti-aging.

Abstract: Various pharmaceutical applications of low-molecular-weight hyaluronic acid (LMW-HA) fragments include: treating tu-mors, conjunctival diseases, xerophthalmia, vitreous opacity, myofascitis, arthritis, cardiovascular diseases, cerebral infarction, dysmenorrhea, endometriosis, periodontal diseases, herpes zoster, burns, pains, pruritus, acute pancreatitis, and postoperative abdominal mucosal adhesions, helping with body recovery after chemotherapy and facial cosmesis, reducing subcutaneous fat etc. Moreover, an injection containing the LMW-HA fragments and a preparation method thereof are disclosed. The injection is injected into the subcutaneous fat layer of the abdomen for facial cosmesis and anti-aging.

Abstract: Various pharmaceutical applications of low-molecular-weight hyaluronic acid (LMW-HA) fragments include: treating tu-mors, conjunctival diseases, xerophthalmia, vitreous opacity, myofascitis, arthritis, cardiovascular diseases, cerebral infarction, dysmenorrhea, endometriosis, periodontal diseases, herpes zoster, burns, pains, pruritus, acute pancreatitis, and postoperative abdominal mucosal adhesions, helping with body recovery after chemotherapy and facial cosmesis, reducing subcutaneous fat etc. Moreover, an injection containing the LMW-HA fragments and a preparation method thereof are disclosed. The injection is injected into the subcutaneous fat layer of the abdomen for facial cosmesis and anti-aging.

Abstract: Various pharmaceutical applications of low-molecular-weight hyaluronic acid (LMW-HA) fragments include: treating to-mors, conjunctival diseases, xerophthalmia, vitreous opacity, myofascitis, arthritis, cardiovascular diseases, cerebral infaretion, dysmenorrhea, endometriosis, periodontal diseases, herpes zoster, burns, pains, pruritus, acute pancreatitis, and postoperative abdominal mucosal adhesions, helping with body recovery after chemotherapy and facial cosmesis, reducing subcutaneous fat etc. Moreover, an injection containing the LMW-HA fragments and a preparation method thereof are disclosed. The injection is injected into the subcutaneous fat layer of the abdomen for facial cosmesis and anti-aging.

Abstract: Various pharmaceutical applications of low-molecular-weight hyaluronic acid (LMW-HA) fragments include: treating tumors, conjunctival diseases, xerophthalmia, vitreous opacity, myofascitis, arthritis, cardiovascular diseases, cerebral infarction, dysmenorrhea, endometriosis, periodontal diseases, herpes zoster, burns, pains, pruritus, acute pancreatitis, and postoperative abdominal mucosal adhesions, helping with body recovery after chemotherapy and facial cosmesis, reducing subcutaneous fat etc. Moreover, an injection containing the LMW-HA fragments and a preparation method thereof are disclosed. The injection is injected into the subcutaneous fat layer of the abdomen for facial cosmesis and anti-aging.

Abstract: Various pharmaceutical applications of low-molecular-weight hyaluronic acid (LMW-HA) fragments include: treating tumors, conjunctival diseases, xerophthalmia, vitreous opacity, myofascitis, arthritis, cardiovascular diseases, cerebral infaretion, dysmenorrhea, endometriosis, periodontal diseases, herpes zoster, burns, pains, pruritus, acute pancreatitis, and postoperative abdominal mucosal adhesions, helping with body recovery after chemotherapy and facial cosmesis, reducing subcutaneous fat etc. Moreover, an injection containing the LMW-HA fragments and a preparation method thereof are disclosed. The injection is injected into the subcutaneous fat layer of the abdomen for facial cosmesis and anti-aging.

Abstract: Various pharmaceutical applications of low-molecular-weight hyaluronic acid (LMW-HA) fragments include: treating tumors, conjunctival diseases, xerophthalmia, vitreous opacity, myofascitis, arthritis, cardiovascular diseases, cerebral infaretion, dysmenorrhea, endometriosis, periodontal diseases, herpes zoster, burns, pains, pruritus, acute pancreatitis, and postoperative abdominal mucosal adhesions, helping with body recovery after chemotherapy and facial cosmesis, reducing subcutaneous fat etc. Moreover, an injection containing the LMW-HA fragments and a preparation method thereof are disclosed. The injection is injected into the subcutaneous fat layer of the abdomen for facial cosmesis and anti-aging.

Abstract: Basing on study of a previous discovered effective bioreactor system, a method to increase culture medium dissolved oxygen is disclosed. This method together with addition of an optimal mixing forms a theoretical foundation for effective bioreactor design and prototype construction.

Abstract: Disclosed are bioreactor systems and methods to transfer a gaseous composition into a liquid composition in a closed environment. Also disclosed are bioreactor systems and methods for high-density culture of microorganisms and stably culture of activated sludge.

Abstract: A method to use chick beta actin gene intron-1 or functional equivalent as a gene expression enhancer element or a gene expression “hot spot” sequence for constructing or reconstructing a mammalian expression vector for extremely high expression of recombinant proteins is disclosed. Composition of a set of extremely strong gene expression vectors is also disclosed.

Abstract: Basing on study of a previous discovered effective bioreactor system, a method to increase culture medium dissolved oxygen is disclosed. This method together with addition of an optimal mixing forms a theoretical foundation for effective bioreactor design and prototype construction.

Abstract: A chimeric polypeptide comprising a TNF neutralizer domain, an IL-1 receptor antagonist domain, and a dimerization domain, wherein the three domains are operably linked to each other. Within the scope of this invention are (i) nucleic acids encoding the polypeptide; (ii) expression vectors and host cells containing the nucleic acids; (iii) related pharmaceutical compositions; and (iii) related preparation and treatment methods.

Abstract: Disclosed are various examples of methods and systems for providing an oxygenated culture environment for growing animal cells, as well as methods and systems for oxygenating blood and related methods for treating diseases and related conditions.

Abstract: A fusion protein including (i) a first segment that is located at the amino terminus of the fusion protein and contains the sequence of a first biological active peptide or protein; and (ii) a second segment that is located at the carboxyl terminus of the fusion protein and contains the sequence of a second biological active peptide or protein. The first and second segments are operably and covalently linked. Also disclosed are nucleic acids encoding the fusion protein, vectors and host cells having the nucleic acids, and related composition and methods of treating diabetes or/and obesity.

Abstract: A fusion protein containing a first segment that is located at the amino terminus of the fusion protein and specifically binds to and neutralizes a first cytokine or growth factor; and a second segment that is located at the carboxyl terminus of the fusion protein and specifically binds to a second cytokine receptor which is often rich at disease sites such as IL-1 receptor-rich inflammatory site. In addition, the said second segment is usually the receptor antagonist such as IL-1 receptor antagonist and its functional equivalent analogues. Also disclosed are nucleic acids encoding the fusion protein, vectors and host cells having the nucleic acids, and related composition and methods to target inflammatory diseases and indications co-existed with inflammation.

Abstract: A cell culture vessel comprising a housing chamber which has an inverted frusto-conical bottom having a vertical axis. The culture vessel further comprises an upper and lower section which are concentric. The vessel requires little or no shear-force and less stress by shaking or impellor action.

Abstract: A chimeric polypeptide comprising a TNF neutralizer domain, an IL-1 receptor antagonist domain, and a dimerization domain, wherein the three domains are operably linked to each other. Within the scope of this invention are (i) nucleic acids encoding the polypeptide; (ii) expression vectors and host cells containing the nucleic acids; (iii) related pharmaceutical compositions; and (iii) related preparation and treatment methods.